NEW YORK (GenomeWeb News) – RayBiotech announced on Tuesday a partnership to provide biomarker discovery and validation services to the Fox Chase Cancer Center.

The deal with the center's Genomics Core Facility also will provide RayBiotech's GMP-compliant and ISO 13485:2003-certified diagnostic discovery products to researchers throughout Fox Chase's campus. The services and products are based on RayBiotech's antibody array and ELISA product lines, the Norcross, Ga.-based firm said, adding Fox Chase is receiving preferred pricing as part of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.